BTD...Vaccine... Competition.BTD timeline.
In the last PressRelease TLT said " Completion of the 450 day assesments for 25 patients, expected in 4Q2022.
It's a good sign that in spite of the Covid-19 crisis the timeline didn't change(BTD application still in Dec 22).
Vaccine.
TLT said " TLT is currently developing a new Light Activation Platform, the TLC-3000B. The TLC-3000B is expected to be completed
for use by PHAC(Public Health Agency Of Canada) & NRC(National Research Council Of Canada) in 1Q2023.
Meaning...The request for the TLC-3000B came from the Government Of Canada.The preliminary results must have been quite good for the Government to ask TLT to develop a new "Light Activated Platform"(TLC-3000B), specifically for vaccine testing purpose.
The SP.
For me the SP is were it should be. I agree with people that say, big investors & big funds will only invest in TLT when revenue will start to come in, until then they sit on the side-line and wait for AA.
Competitions.
1) BCG...
BCG is the standard of care, unfortunately there is a shortage of BCG.
https://discover.vumc.org/2021/02/bcg-shortages/will-persist/ As we speak, patients are placed on a waiting list for BCG treatments, during that time their cancer could be progressing.
2) Keytruda...
Keytruda as a low CR% and a lot's of side effect.
3) ImmunityBio.
ImminutyBio is a good treatment with a good CR%(as good as TLT treatment).
Unfortunately each patients need to start with 6 treatments in six weeks of BCG+N-803 and maintenance treatments of BCG+N-803 for up to 3 years.
That is a long time and a lot's of BCG treatments for just one patients.
Because of the shortage of BCG & and the high number of treatments needed for just one patient, the waiting list for the ImmunityBio patients could be very long, and by the time BCG is available the patient could have lost it's bladder.
The lack of good competitions could force the FDA to look for a good stand alone treatment with a good CR% and very low side effects.
We are on the verge of finding out, if TLT treatment is what the FDA is looking for.